Riskpilot← Back to searchSign inGet full accessNORGESGRUPPEN HELSE AS
ASActiveOrg 916602162Alf Bjerckes Vei 28, 0582 OsloRetail sale of pharmaceutical products · NACE 4773Est. 20160 employees
Revenue 2025
NOK 0
EBITDA margin
—
+2% vs 2024
Equity ratio
84.3%
Financial strength
Net profit 2025
NOK 397,2M
+42% vs 2024
| Revenue | NOK 0 | — |
| EBITDA | NOK -204K | +2% |
| Net profit | NOK 397,2M | +42% |
| Total assets | NOK 3,6B | +14% |
| Equity | NOK 3,1B | -1% |
| Employees | 0 | — |
Legal name
NORGESGRUPPEN HELSE AS
Org number
916602162
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
21. januar 2016
Share capital
NOK 150 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-03-31
Financial year
January – December
Company purpose
Å eie aksjer og investere i andre selskaper.
Address
Alf Bjerckes Vei 28, 0582 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −202 | −133 | −271 | −208 | −204 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −202 | −133 | −271 | −208 | −204 |
| Net financials | −187 136 | −187 139 | −984 550 | 163 407 | 509 393 |
| Profit before tax | −187 338 | −187 272 | −984 821 | 163 199 | 509 189 |
| Tax | −16 812 | −17 974 | −23 409 | −115 893 | 112 006 |
| Net profit | −170 526 | −169 298 | −961 412 | 279 092 | 397 183 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 4 541 922 | 4 289 213 | 3 151 346 | 3 195 419 | 3 627 698 |
| Equity | 1 234 111 | 972 883 | 2 812 272 | 3 091 363 | 3 056 546 |
| Long-term debt | 3 000 000 | 3 000 000 | 0 | 0 | 0 |
| Short-term debt | 307 811 | 316 330 | 339 074 | 104 056 | 571 152 |
| Total debt | 3 307 811 | 3 316 330 | 339 074 | 104 056 | 571 152 |
EBITDA margin
-20400000.0%
This company
15.8%
Market median
-129114024% vs market
20212025
Equity ratio
84.3%
This company
38.2%
Market median
+121% vs market
20212025
Return on equity
13.0%
This company
18.4%
Market median
+29% vs market
20212025
Net profit margin
39718300000.0%
This company
8.1%
Market median
+490349382616% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.19×
This company
0.62×
Market median
+69% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2020-04-01 – 2021-03-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
VH Contact Person | Contact Person | 2016 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Chairman | 2026 | |
| Board of Directors | 2020 | |
| Board of Directors | 2025 | |
| Chairman | 2020 | |
| Board of Directors | 2026 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Mckesson Europe Services Gmbh | Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NORGESGRUPPEN HELSE AS (this company)
Norsk Medisinaldepot AsBoard members of NORGESGRUPPEN HELSE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Vegard Hoff | Contact Person | 0 companies |
| Finn Torstein Dybvik | Chairman | 0 companies |
| Ros-Marie Soo Yeun Grusén | Board of Directors | 0 companies |
| Terje Kvaal | Board of Directors | 0 companies |
| Michael Roland Ecker | Chairman | 0 companies |
| Rune Spikseth | Board of Directors | 0 companies |